[Molecular markers of the cervical cancer].
The genome of human papilloma viruses from a high-risk group (HPV types 16 and 18) has been detected in 90% of cervical tumors and, in some cases, in the adjacent normal tissues. The presence of viral DNA is the main molecular marker of this neoplasia. HPV genome may persist in the tumors as episomal and integrative forms at early and late stages of tumor progression. The status of viral DNA and the pattern of its expression are similar in all cells of this tumor cell population and seem to be a marker of tumor cell monoclonality. Antibodies to the products of viral oncogenes E6 and E7 were found only in 35% of the patients with tumor where HPV genome is present. Thus, this criteria cannot be used for diagnostic and prognostic purposes. On chromosome 6 in the cervical tumors, the specific marker of heterozygocity on loci 6p21.3 was found. The marker appears at the precancer stage and may be regarded as a marker of tumor monoclonality. Heterozygocity loss in the specific locus in the region 6q16-21 correlates with tumor progression and suggests that there are potential tumor-suppressor genes in this region of chromosome 6. A group of HPV positive tumors with a hypermethylator phenotype is described. These tumors are characterized by the simultaneous methylation and inactivation of multiple genes, including tumor suppressor genes.
Kiselev
F L
FL
Mazurenko
N N
NN
Kiseleva
N P
NP
Kobzeva
V K
VK
Semenova
L A
LA
Pavlova
L S
LS
Beliakov
I S
IS
Bliev
A Iu
AIu
Eshilev
E M
EM
Ivanova
T A
TA
Petrenko
A A
AA
D005260:Female; D005819:Genetic Markers; D006801:Humans; D030361:Papillomavirus Infections / Q000235:genetics* / Q000821:virology*; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000821:virology*
D005819:Genetic Markers